CA Patent

CA2341400A1 — Methods and compositions employing optically pure s(+) vigabatrin

Assigned to Sumitomo Pharma America Inc · Expires 2000-03-02 · 26y expired

What this patent protects

Methods and compositions for the prevention, treatment, and/or management of the symptoms of peripheral neuropathy and related disorders, drug or alcohol addiction or the symptoms thereof, or symptoms associated with drug or alcohol withdrawal, using substantially optically pure …

USPTO Abstract

Methods and compositions for the prevention, treatment, and/or management of the symptoms of peripheral neuropathy and related disorders, drug or alcohol addiction or the symptoms thereof, or symptoms associated with drug or alcohol withdrawal, using substantially optically pure S(+) vigabatrin, or a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

Patent Metadata

Patent number
CA2341400A1
Jurisdiction
CA
Classification
Expires
2000-03-02
Drug substance claim
No
Drug product claim
No
Assignee
Sumitomo Pharma America Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.